{"gene":"BAALC","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2001,"finding":"BAALC protein localizes to the cytoplasm and in vitro studies suggest a function in the cytoskeleton network. Five protein isoforms are produced from complex splicing of eight transcripts.","method":"Subcellular localization studies in vitro; genomic characterization and splice variant analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, localization inferred from in vitro studies with no functional validation described in abstract","pmids":["11707601"],"is_preprint":false},{"year":2003,"finding":"BAALC expression is restricted to CD34+ hematopoietic progenitor cells (including CD34+/CD38-, CD34+/CD33+, and lineage-committed CD34+ fractions) and is downregulated during in vitro differentiation with lineage-specific cytokines (G-CSF, M-CSF, EPO) as early as day 4, indicating stage-specific expression tied to progenitor identity.","method":"FACS sorting of bone marrow subpopulations followed by real-time RT-PCR; in vitro differentiation assays with cytokine stimulation","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FACS-sorted populations with RT-PCR plus functional differentiation assay, single lab but two orthogonal approaches","pmids":["14585369"],"is_preprint":false},{"year":2005,"finding":"BAALC 1-6-8 isoform protein is targeted to postsynaptic lipid rafts via N-terminal myristoylation and palmitoylation; both modifications are required for raft targeting. The protein physically interacts with CaMKIIα (but not CaMKIIβ) through its N-terminal 35-amino-acid region binding to the C-terminal regulatory domain of CaMKIIα. The protein localizes to synaptic sites and increases during synaptogenesis.","method":"Co-immunoprecipitation/pull-down interaction assay; lipid raft fractionation; mutagenesis of myristoylation and palmitoylation sites; immunolocalization in rat brain","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding assay with domain-level mutagenesis, lipid raft fractionation, and localization, multiple orthogonal methods in one study","pmids":["15659234"],"is_preprint":false},{"year":2005,"finding":"Baalc protein localizes to the cytoplasm adjacent to the cell membrane in muscle cells and co-localizes with known muscle-associated proteins but not with neural crest or neuronal markers, identifying it as a marker of the mesodermal/muscle lineage in mouse embryos.","method":"Immunohistochemical analysis of embryonic and adult mouse tissues","journal":"Gene expression patterns : GEP","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, immunohistochemistry only, no functional validation","pmids":["15749074"],"is_preprint":false},{"year":2005,"finding":"BAALC expression is induced in astrocytes upon treatment with differentiation inducers (inhibition of proliferation), suggesting a role in the astrocyte differentiation/proliferation balance.","method":"mRNA differential display analysis of primary astrocytes treated with differentiation inducers","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, expression-based differential display, no functional mechanistic follow-up","pmids":["16376586"],"is_preprint":false},{"year":2011,"finding":"BAALC gene promoter activity is regulated by histone post-translational modifications (H3K9K14 acetylation, H3K4 trimethylation, H3K23 trimethylation), with distinct epigenetic profiles associated with high versus low BAALC expression in leukemia cell lines, consistent with a 'paused' transcriptional state.","method":"Chromatin immunoprecipitation (ChIP) analysis of histone modifications at the BAALC promoter in leukemia cell lines","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP assay directly at BAALC promoter, single lab, single method","pmids":["22197554"],"is_preprint":false},{"year":2012,"finding":"shRNA-mediated knockdown of BAALC in the KG1a AML cell line results in decreased proliferation and enhanced apoptosis, demonstrating a functional role for BAALC in promoting leukemia cell survival and proliferation.","method":"shRNA knockdown in AML cell line (KG1a); growth curve analysis and FACS apoptosis assay","journal":"Hematology (Amsterdam, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean KD with defined cellular phenotype (proliferation + apoptosis), single lab, single cell line","pmids":["22549446"],"is_preprint":false},{"year":2012,"finding":"A SNP (rs62527607[GT]) in the BAALC promoter region creates a binding site for the RUNX1 transcription factor; the T allele drives higher BAALC expression in an allele-specific manner, establishing RUNX1 as a transcriptional activator of BAALC.","method":"Luciferase reporter assay; electrophoretic mobility shift assay (EMSA); in vivo association with RUNX1 expression status in AML patient cohorts (test set n=253, validation n=105)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — luciferase reporter + EMSA (two orthogonal in vitro methods) validated in two independent patient cohorts","pmids":["22493267"],"is_preprint":false},{"year":2014,"finding":"miR-3151, located in intron 1 of BAALC, has its own regulatory element that partly uncouples its expression from the BAALC transcript. Both miR-3151 and BAALC are transcriptionally activated by a SP1/NF-κB complex, whereas BAALC (but not miR-3151) is additionally stimulated by RUNX1.","method":"Reporter assays and transcription factor binding studies in AML cell lines; miRNA overexpression/knockdown in cell lines and mouse leukemogenesis model","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple complementary assays in one study (reporter assay, TF binding, in vivo mouse model), single lab","pmids":["24736457"],"is_preprint":false},{"year":2015,"finding":"BAALC physically interacts with the scaffold protein MEKK1 (MAP3K1), inhibiting the interaction between ERK and its phosphatase MKP3/DUSP6, thereby sustaining ERK activity and promoting cell-cycle progression and chemoresistance. Separately, BAALC traps the transcription factor KLF4 in the cytoplasm, preventing nuclear KLF4-mediated monocytic differentiation of AML cells.","method":"Co-immunoprecipitation of BAALC-MEKK1 and BAALC-KLF4 complexes; ERK activity assays; cytoplasmic/nuclear fractionation for KLF4 localization; MEK inhibitor treatment in vitro and in vivo mouse model; ABC transporter expression analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — reciprocal Co-IP for two binding partners, subcellular fractionation, in vitro and in vivo functional validation with pharmacological rescue, multiple orthogonal methods","pmids":["26050649"],"is_preprint":false},{"year":2021,"finding":"BAALC physically interacts with DBN1 (Drebrin 1), an actin-binding protein. This interaction promotes cell adhesion to bone marrow stromal cells; DBN1 knockdown impairs adhesion and restores sensitivity to cytarabine, indicating the BAALC-DBN1 interaction contributes to microenvironment-mediated chemoresistance.","method":"Mass spectrometry identification of BAALC binding partners; functional cell adhesion assays with DBN1 knockdown; cytarabine sensitivity assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-identified interaction with functional adhesion and drug sensitivity validation, single lab, two orthogonal methods","pmids":["33453340"],"is_preprint":false},{"year":2021,"finding":"BAALC upregulation in CN/AML cells results in phosphorylation of MK2a (MAPKAPK2); genetic deletion of BAALC or pharmacological inhibition of MK2a phosphorylation (with CMPD1) blocks proliferation and induces differentiation of CN/AML blasts selectively without affecting normal hematopoietic stem and progenitor cells.","method":"CRISPR-Cas9 deletion of BAALC in iPSC-derived CN/AML HSPCs; phosphoproteomic identification of MK2a as downstream effector; CMPD1 inhibitor treatment in primary patient blasts and iPSC-derived HSPCs; colony and differentiation assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR KO with defined phenotype, pharmacological inhibitor validation in primary blasts and iPSC model, multiple orthogonal methods in one study","pmids":["33894142"],"is_preprint":false},{"year":2021,"finding":"BAALC overexpression in MCF-7 breast cancer cells increases proliferation, anchorage-independent growth, invasion, and migration; siRNA knockdown in Hs578T cells decreases these properties. The migration and invasion effect is mediated by FAK (focal adhesion kinase)-dependent signaling and is accompanied by increased MMP-9 (but not MMP-2) activity.","method":"BAALC overexpression in MCF-7; siRNA knockdown in Hs578T; proliferation assay, invasion/migration assay, gelatin zymography for MMP activity, FAK inhibitor treatment","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain- and loss-of-function with pharmacological pathway validation (FAK inhibitor) and MMP activity assay, single lab","pmids":["33968759"],"is_preprint":false},{"year":2020,"finding":"NMR backbone resonance assignments (1H, 13C, 15N) were completed for the longest hematopoietic isoform (isoform 1) of human BAALC, providing the first structural characterization of the protein backbone. Comparison with the shortest neuroectodermal isoform (isoform 6) showed only minor chemical shift differences.","method":"Solution NMR spectroscopy (backbone assignment of 180-residue protein)","journal":"Biomolecular NMR assignments","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — NMR structural data (backbone assignments) but no functional validation reported; single lab, partial structural characterization","pmids":["32240523"],"is_preprint":false}],"current_model":"BAALC is a cytoplasmic, membrane-associated protein (targeted to lipid rafts via N-terminal myristoylation/palmitoylation in neurons) that acts as a scaffold/adaptor: in leukemia cells it sustains oncogenic ERK signaling by binding MEKK1 and blocking MKP3/DUSP6-mediated ERK dephosphorylation, sequesters the transcription factor KLF4 in the cytoplasm to block myeloid differentiation, interacts with the actin-binding protein DBN1 to promote stromal adhesion and chemoresistance, and drives MK2a phosphorylation to support leukemic proliferation; its transcription is activated by a RUNX1-binding promoter SNP and by SP1/NF-κB, and its expression is epigenetically regulated via histone modifications, with expression restricted to CD34+ hematopoietic progenitors and downregulated upon differentiation."},"narrative":{"mechanistic_narrative":"BAALC encodes a small, membrane-associated cytoplasmic scaffold/adaptor protein whose stage-restricted expression marks CD34+ hematopoietic progenitors and is downregulated as cells commit to myeloid lineages [PMID:14585369]. In neurons the 1-6-8 isoform is anchored to postsynaptic lipid rafts through N-terminal myristoylation and palmitoylation and binds the regulatory domain of CaMKIIα, establishing a raft-targeted adaptor function [PMID:15659234]. In leukemia, BAALC functions as an oncogenic scaffold: it binds MEKK1 (MAP3K1) and blocks MKP3/DUSP6-mediated ERK dephosphorylation to sustain ERK activity, while simultaneously sequestering the transcription factor KLF4 in the cytoplasm to block monocytic differentiation, together driving cell-cycle progression and chemoresistance [PMID:26050649]. It additionally signals through phosphorylation of MK2a (MAPKAPK2), and its loss selectively halts proliferation and induces differentiation of CN/AML blasts without affecting normal HSPCs [PMID:33894142], and it interacts with the actin-binding protein DBN1 to promote stromal adhesion and microenvironment-mediated chemoresistance [PMID:33453340]. Functionally, BAALC promotes leukemia cell survival and proliferation, as knockdown reduces growth and increases apoptosis [PMID:22549446]. Its transcription is activated by a RUNX1-binding promoter SNP and by an SP1/NF-κB complex, and is shaped by histone modifications consistent with a paused promoter state [PMID:22493267, PMID:24736457, PMID:22197554].","teleology":[{"year":2001,"claim":"Establishing the basic cell biology of BAALC as a cytoplasmic protein with multiple isoforms was the first step toward assigning any function.","evidence":"Subcellular localization and genomic/splice-variant analysis in vitro","pmids":["11707601"],"confidence":"Low","gaps":["Localization inferred in vitro with no functional validation","Roles of individual isoforms undefined","No binding partners identified"]},{"year":2003,"claim":"Defining where BAALC is normally expressed linked it to progenitor identity, framing why its dysregulation matters in leukemia.","evidence":"FACS sorting of bone marrow subpopulations with RT-PCR plus cytokine-driven differentiation assays","pmids":["14585369"],"confidence":"Medium","gaps":["Expression pattern does not establish a causal function","Mechanism of downregulation upon differentiation unknown"]},{"year":2005,"claim":"Identifying lipid-raft targeting via lipidation and a direct CaMKIIα interaction revealed BAALC as a membrane-anchored adaptor in neurons.","evidence":"Co-IP/pull-down, raft fractionation, and mutagenesis of myristoylation/palmitoylation sites in rat brain","pmids":["15659234"],"confidence":"High","gaps":["Functional consequence of CaMKIIα binding for synapse physiology not resolved","Whether raft targeting applies to hematopoietic isoforms unknown"]},{"year":2012,"claim":"Loss-of-function established BAALC as functionally required for leukemia cell survival rather than merely a marker.","evidence":"shRNA knockdown in KG1a AML cells with proliferation and apoptosis readouts","pmids":["22549446"],"confidence":"Medium","gaps":["Single cell line","Molecular mechanism downstream of BAALC not addressed"]},{"year":2012,"claim":"Discovery of a RUNX1-binding promoter SNP explained allele-specific transcriptional control of BAALC and connected it to a master hematopoietic regulator.","evidence":"Luciferase reporter and EMSA validated across two AML patient cohorts","pmids":["22493267"],"confidence":"High","gaps":["Does not address post-transcriptional or epigenetic layers of regulation"]},{"year":2014,"claim":"Mapping the SP1/NF-κB and RUNX1 inputs and the embedded miR-3151 clarified the shared and separable transcriptional control of the BAALC locus.","evidence":"Reporter assays, TF-binding studies, and miRNA gain/loss in cell lines and a mouse leukemogenesis model","pmids":["24736457"],"confidence":"Medium","gaps":["Relative contribution of each TF in vivo unclear","Functional separation of miR-3151 vs BAALC effects incomplete"]},{"year":2015,"claim":"Identifying the MEKK1 and KLF4 interactions provided the first molecular mechanism by which BAALC sustains ERK signaling and blocks differentiation.","evidence":"Reciprocal Co-IP, nuclear/cytoplasmic fractionation, ERK activity assays, and MEK inhibition in vitro and in vivo","pmids":["26050649"],"confidence":"High","gaps":["Structural basis of MEKK1 and KLF4 binding not defined","How one scaffold coordinates both interactions unknown"]},{"year":2020,"claim":"NMR backbone assignment provided the first structural foothold for an otherwise poorly characterized protein and showed isoforms share a similar backbone.","evidence":"Solution NMR backbone assignment of the 180-residue hematopoietic isoform 1","pmids":["32240523"],"confidence":"Medium","gaps":["No folded domain or interaction interface determined","Functional mapping of structure to partner binding absent"]},{"year":2021,"claim":"CRISPR deletion and phosphoproteomics pinpointed MK2a as a BAALC effector and demonstrated a leukemia-selective therapeutic vulnerability.","evidence":"CRISPR-Cas9 KO in iPSC-derived CN/AML HSPCs, phosphoproteomics, and CMPD1 inhibition in primary blasts","pmids":["33894142"],"confidence":"High","gaps":["Direct biochemical link between BAALC and MK2a phosphorylation not shown","Relationship to the ERK/MEKK1 axis not integrated"]},{"year":2021,"claim":"Identifying the DBN1 interaction connected BAALC to actin-dependent stromal adhesion and microenvironmental chemoresistance.","evidence":"Mass spectrometry interaction mapping with DBN1 knockdown adhesion and cytarabine sensitivity assays","pmids":["33453340"],"confidence":"Medium","gaps":["Interaction not confirmed by reciprocal Co-IP","Direct vs indirect binding unresolved"]},{"year":2021,"claim":"Reciprocal gain/loss-of-function in breast cancer cells extended BAALC's pro-tumorigenic scaffold role beyond hematopoiesis via FAK/MMP-9 signaling.","evidence":"Overexpression and siRNA knockdown in breast cancer lines with FAK inhibitor and gelatin zymography","pmids":["33968759"],"confidence":"Medium","gaps":["Whether BAALC binds FAK directly not established","Generalizability across solid tumors unknown"]},{"year":null,"claim":"How a single small lipidated scaffold coordinates its distinct partner interactions (MEKK1, KLF4, DBN1, CaMKIIα) and links to MK2a phosphorylation at the structural and biochemical level remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of any BAALC-partner complex","Direct enzymatic versus purely scaffolding role undefined","Mechanism integrating ERK, MK2a, and adhesion pathways unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2,9,10]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,3,9]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[9,11]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[7,8]}],"complexes":[],"partners":["MAP3K1","KLF4","DBN1","CAMK2A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8WXS3","full_name":"Brain and acute leukemia cytoplasmic protein","aliases":[],"length_aa":145,"mass_kda":15.6,"function":"May play a synaptic role at the postsynaptic lipid rafts possibly through interaction with CAMK2A","subcellular_location":"Cytoplasm; Synapse, synaptosome; Membrane raft; Postsynaptic density","url":"https://www.uniprot.org/uniprotkb/Q8WXS3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BAALC","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BAALC","total_profiled":1310},"omim":[{"mim_id":"606602","title":"BRAIN AND ACUTE LEUKEMIA GENE, CYTOPLASMIC; BAALC","url":"https://www.omim.org/entry/606602"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":274.0}],"url":"https://www.proteinatlas.org/search/BAALC"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q8WXS3","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WXS3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WXS3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8WXS3-F1-predicted_aligned_error_v6.png","plddt_mean":60.09},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BAALC","jax_strain_url":"https://www.jax.org/strain/search?query=BAALC"},"sequence":{"accession":"Q8WXS3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8WXS3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8WXS3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8WXS3"}},"corpus_meta":[{"pmid":"12750167","id":"PMC_12750167","title":"BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12750167","citation_count":182,"is_preprint":false},{"pmid":"11707601","id":"PMC_11707601","title":"BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11707601","citation_count":112,"is_preprint":false},{"pmid":"17646667","id":"PMC_17646667","title":"Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.","date":"2007","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17646667","citation_count":73,"is_preprint":false},{"pmid":"14585369","id":"PMC_14585369","title":"BAALC, a novel marker of human hematopoietic progenitor cells.","date":"2003","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14585369","citation_count":61,"is_preprint":false},{"pmid":"22529287","id":"PMC_22529287","title":"miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22529287","citation_count":58,"is_preprint":false},{"pmid":"20065290","id":"PMC_20065290","title":"High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20065290","citation_count":51,"is_preprint":false},{"pmid":"21835957","id":"PMC_21835957","title":"Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21835957","citation_count":43,"is_preprint":false},{"pmid":"32811810","id":"PMC_32811810","title":"Long non-coding RNA LRRC75A-AS1 facilitates triple negative breast cancer cell proliferation and invasion via functioning as a ceRNA to modulate BAALC.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32811810","citation_count":34,"is_preprint":false},{"pmid":"26050649","id":"PMC_26050649","title":"BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4.","date":"2015","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/26050649","citation_count":28,"is_preprint":false},{"pmid":"33894142","id":"PMC_33894142","title":"iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropenia.","date":"2021","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/33894142","citation_count":24,"is_preprint":false},{"pmid":"15659234","id":"PMC_15659234","title":"BAALC 1-6-8 protein is targeted to postsynaptic lipid rafts by its N-terminal myristoylation and palmitoylation, and interacts with alpha, but not beta, subunit of Ca/calmodulin-dependent protein kinase II.","date":"2005","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15659234","citation_count":23,"is_preprint":false},{"pmid":"33476486","id":"PMC_33476486","title":"BAALC-AS1/G3BP2/c-Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma.","date":"2021","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33476486","citation_count":22,"is_preprint":false},{"pmid":"25428390","id":"PMC_25428390","title":"Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.","date":"2014","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25428390","citation_count":20,"is_preprint":false},{"pmid":"22493267","id":"PMC_22493267","title":"Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22493267","citation_count":20,"is_preprint":false},{"pmid":"24736457","id":"PMC_24736457","title":"Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24736457","citation_count":19,"is_preprint":false},{"pmid":"29152132","id":"PMC_29152132","title":"High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29152132","citation_count":18,"is_preprint":false},{"pmid":"18631381","id":"PMC_18631381","title":"BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC.","date":"2008","source":"Journal of carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18631381","citation_count":17,"is_preprint":false},{"pmid":"22549446","id":"PMC_22549446","title":"shRNA-Mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells.","date":"2012","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/22549446","citation_count":16,"is_preprint":false},{"pmid":"23672350","id":"PMC_23672350","title":"BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.","date":"2013","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/23672350","citation_count":15,"is_preprint":false},{"pmid":"24855032","id":"PMC_24855032","title":"Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.","date":"2014","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24855032","citation_count":12,"is_preprint":false},{"pmid":"20376583","id":"PMC_20376583","title":"Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.","date":"2010","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/20376583","citation_count":12,"is_preprint":false},{"pmid":"23647058","id":"PMC_23647058","title":"Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.","date":"2013","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/23647058","citation_count":8,"is_preprint":false},{"pmid":"29296827","id":"PMC_29296827","title":"Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.","date":"2017","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/29296827","citation_count":7,"is_preprint":false},{"pmid":"22197554","id":"PMC_22197554","title":"Histone post-translational modifications associated to BAALC expression in leukemic cells.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22197554","citation_count":7,"is_preprint":false},{"pmid":"27372260","id":"PMC_27372260","title":"Evaluation of rs62527607 [GT] single nucleotide polymorphism located in BAALC gene in children with acute leukemia using mismatch PCR-RFLP.","date":"2016","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27372260","citation_count":7,"is_preprint":false},{"pmid":"16376586","id":"PMC_16376586","title":"Induction of BAALC and down regulation of RAMP3 in astrocytes treated with differentiation inducers.","date":"2005","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/16376586","citation_count":6,"is_preprint":false},{"pmid":"15749074","id":"PMC_15749074","title":"Baalc, a marker of mesoderm and muscle.","date":"2005","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/15749074","citation_count":5,"is_preprint":false},{"pmid":"27335598","id":"PMC_27335598","title":"BAALC and ERG Expression in Egyptian Patients with Acute Myeloid Leukemia, Relation to Survival and Response to Treatment.","date":"2016","source":"Open access Macedonian journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27335598","citation_count":4,"is_preprint":false},{"pmid":"33453340","id":"PMC_33453340","title":"Physical interaction between BAALC and DBN1 induces chemoresistance in leukemia.","date":"2021","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33453340","citation_count":3,"is_preprint":false},{"pmid":"33747867","id":"PMC_33747867","title":"WT-1, BAALC, and ERG Expressions in Iranian Patients with Acute Myeloid Leukemia Pre- and Post-chemotherapy.","date":"2020","source":"Advanced pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/33747867","citation_count":3,"is_preprint":false},{"pmid":"33968759","id":"PMC_33968759","title":"A Novel Role for Brain and Acute Leukemia Cytoplasmic (BAALC) in Human Breast Cancer Metastasis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33968759","citation_count":3,"is_preprint":false},{"pmid":"36315178","id":"PMC_36315178","title":"Study of mRNA of WT1, BAALC, EVI1, PRAME and HMGA2 genes in whole blood samples.","date":"2022","source":"Klinicheskaia laboratornaia diagnostika","url":"https://pubmed.ncbi.nlm.nih.gov/36315178","citation_count":0,"is_preprint":false},{"pmid":"32240523","id":"PMC_32240523","title":"1H, 13C, and 15N Backbone assignments of the human brain and acute leukemia cytoplasmic (BAALC) protein.","date":"2020","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/32240523","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18256,"output_tokens":3509,"usd":0.053701,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11083,"output_tokens":3326,"usd":0.069282,"stage2_stop_reason":"end_turn"},"total_usd":0.122983,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"BAALC protein localizes to the cytoplasm and in vitro studies suggest a function in the cytoskeleton network. Five protein isoforms are produced from complex splicing of eight transcripts.\",\n      \"method\": \"Subcellular localization studies in vitro; genomic characterization and splice variant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, localization inferred from in vitro studies with no functional validation described in abstract\",\n      \"pmids\": [\"11707601\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BAALC expression is restricted to CD34+ hematopoietic progenitor cells (including CD34+/CD38-, CD34+/CD33+, and lineage-committed CD34+ fractions) and is downregulated during in vitro differentiation with lineage-specific cytokines (G-CSF, M-CSF, EPO) as early as day 4, indicating stage-specific expression tied to progenitor identity.\",\n      \"method\": \"FACS sorting of bone marrow subpopulations followed by real-time RT-PCR; in vitro differentiation assays with cytokine stimulation\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FACS-sorted populations with RT-PCR plus functional differentiation assay, single lab but two orthogonal approaches\",\n      \"pmids\": [\"14585369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BAALC 1-6-8 isoform protein is targeted to postsynaptic lipid rafts via N-terminal myristoylation and palmitoylation; both modifications are required for raft targeting. The protein physically interacts with CaMKIIα (but not CaMKIIβ) through its N-terminal 35-amino-acid region binding to the C-terminal regulatory domain of CaMKIIα. The protein localizes to synaptic sites and increases during synaptogenesis.\",\n      \"method\": \"Co-immunoprecipitation/pull-down interaction assay; lipid raft fractionation; mutagenesis of myristoylation and palmitoylation sites; immunolocalization in rat brain\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding assay with domain-level mutagenesis, lipid raft fractionation, and localization, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15659234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Baalc protein localizes to the cytoplasm adjacent to the cell membrane in muscle cells and co-localizes with known muscle-associated proteins but not with neural crest or neuronal markers, identifying it as a marker of the mesodermal/muscle lineage in mouse embryos.\",\n      \"method\": \"Immunohistochemical analysis of embryonic and adult mouse tissues\",\n      \"journal\": \"Gene expression patterns : GEP\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, immunohistochemistry only, no functional validation\",\n      \"pmids\": [\"15749074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"BAALC expression is induced in astrocytes upon treatment with differentiation inducers (inhibition of proliferation), suggesting a role in the astrocyte differentiation/proliferation balance.\",\n      \"method\": \"mRNA differential display analysis of primary astrocytes treated with differentiation inducers\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, expression-based differential display, no functional mechanistic follow-up\",\n      \"pmids\": [\"16376586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BAALC gene promoter activity is regulated by histone post-translational modifications (H3K9K14 acetylation, H3K4 trimethylation, H3K23 trimethylation), with distinct epigenetic profiles associated with high versus low BAALC expression in leukemia cell lines, consistent with a 'paused' transcriptional state.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) analysis of histone modifications at the BAALC promoter in leukemia cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP assay directly at BAALC promoter, single lab, single method\",\n      \"pmids\": [\"22197554\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"shRNA-mediated knockdown of BAALC in the KG1a AML cell line results in decreased proliferation and enhanced apoptosis, demonstrating a functional role for BAALC in promoting leukemia cell survival and proliferation.\",\n      \"method\": \"shRNA knockdown in AML cell line (KG1a); growth curve analysis and FACS apoptosis assay\",\n      \"journal\": \"Hematology (Amsterdam, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean KD with defined cellular phenotype (proliferation + apoptosis), single lab, single cell line\",\n      \"pmids\": [\"22549446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A SNP (rs62527607[GT]) in the BAALC promoter region creates a binding site for the RUNX1 transcription factor; the T allele drives higher BAALC expression in an allele-specific manner, establishing RUNX1 as a transcriptional activator of BAALC.\",\n      \"method\": \"Luciferase reporter assay; electrophoretic mobility shift assay (EMSA); in vivo association with RUNX1 expression status in AML patient cohorts (test set n=253, validation n=105)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — luciferase reporter + EMSA (two orthogonal in vitro methods) validated in two independent patient cohorts\",\n      \"pmids\": [\"22493267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-3151, located in intron 1 of BAALC, has its own regulatory element that partly uncouples its expression from the BAALC transcript. Both miR-3151 and BAALC are transcriptionally activated by a SP1/NF-κB complex, whereas BAALC (but not miR-3151) is additionally stimulated by RUNX1.\",\n      \"method\": \"Reporter assays and transcription factor binding studies in AML cell lines; miRNA overexpression/knockdown in cell lines and mouse leukemogenesis model\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple complementary assays in one study (reporter assay, TF binding, in vivo mouse model), single lab\",\n      \"pmids\": [\"24736457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAALC physically interacts with the scaffold protein MEKK1 (MAP3K1), inhibiting the interaction between ERK and its phosphatase MKP3/DUSP6, thereby sustaining ERK activity and promoting cell-cycle progression and chemoresistance. Separately, BAALC traps the transcription factor KLF4 in the cytoplasm, preventing nuclear KLF4-mediated monocytic differentiation of AML cells.\",\n      \"method\": \"Co-immunoprecipitation of BAALC-MEKK1 and BAALC-KLF4 complexes; ERK activity assays; cytoplasmic/nuclear fractionation for KLF4 localization; MEK inhibitor treatment in vitro and in vivo mouse model; ABC transporter expression analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — reciprocal Co-IP for two binding partners, subcellular fractionation, in vitro and in vivo functional validation with pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"26050649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAALC physically interacts with DBN1 (Drebrin 1), an actin-binding protein. This interaction promotes cell adhesion to bone marrow stromal cells; DBN1 knockdown impairs adhesion and restores sensitivity to cytarabine, indicating the BAALC-DBN1 interaction contributes to microenvironment-mediated chemoresistance.\",\n      \"method\": \"Mass spectrometry identification of BAALC binding partners; functional cell adhesion assays with DBN1 knockdown; cytarabine sensitivity assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-identified interaction with functional adhesion and drug sensitivity validation, single lab, two orthogonal methods\",\n      \"pmids\": [\"33453340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAALC upregulation in CN/AML cells results in phosphorylation of MK2a (MAPKAPK2); genetic deletion of BAALC or pharmacological inhibition of MK2a phosphorylation (with CMPD1) blocks proliferation and induces differentiation of CN/AML blasts selectively without affecting normal hematopoietic stem and progenitor cells.\",\n      \"method\": \"CRISPR-Cas9 deletion of BAALC in iPSC-derived CN/AML HSPCs; phosphoproteomic identification of MK2a as downstream effector; CMPD1 inhibitor treatment in primary patient blasts and iPSC-derived HSPCs; colony and differentiation assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR KO with defined phenotype, pharmacological inhibitor validation in primary blasts and iPSC model, multiple orthogonal methods in one study\",\n      \"pmids\": [\"33894142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BAALC overexpression in MCF-7 breast cancer cells increases proliferation, anchorage-independent growth, invasion, and migration; siRNA knockdown in Hs578T cells decreases these properties. The migration and invasion effect is mediated by FAK (focal adhesion kinase)-dependent signaling and is accompanied by increased MMP-9 (but not MMP-2) activity.\",\n      \"method\": \"BAALC overexpression in MCF-7; siRNA knockdown in Hs578T; proliferation assay, invasion/migration assay, gelatin zymography for MMP activity, FAK inhibitor treatment\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain- and loss-of-function with pharmacological pathway validation (FAK inhibitor) and MMP activity assay, single lab\",\n      \"pmids\": [\"33968759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NMR backbone resonance assignments (1H, 13C, 15N) were completed for the longest hematopoietic isoform (isoform 1) of human BAALC, providing the first structural characterization of the protein backbone. Comparison with the shortest neuroectodermal isoform (isoform 6) showed only minor chemical shift differences.\",\n      \"method\": \"Solution NMR spectroscopy (backbone assignment of 180-residue protein)\",\n      \"journal\": \"Biomolecular NMR assignments\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — NMR structural data (backbone assignments) but no functional validation reported; single lab, partial structural characterization\",\n      \"pmids\": [\"32240523\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BAALC is a cytoplasmic, membrane-associated protein (targeted to lipid rafts via N-terminal myristoylation/palmitoylation in neurons) that acts as a scaffold/adaptor: in leukemia cells it sustains oncogenic ERK signaling by binding MEKK1 and blocking MKP3/DUSP6-mediated ERK dephosphorylation, sequesters the transcription factor KLF4 in the cytoplasm to block myeloid differentiation, interacts with the actin-binding protein DBN1 to promote stromal adhesion and chemoresistance, and drives MK2a phosphorylation to support leukemic proliferation; its transcription is activated by a RUNX1-binding promoter SNP and by SP1/NF-κB, and its expression is epigenetically regulated via histone modifications, with expression restricted to CD34+ hematopoietic progenitors and downregulated upon differentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BAALC encodes a small, membrane-associated cytoplasmic scaffold/adaptor protein whose stage-restricted expression marks CD34+ hematopoietic progenitors and is downregulated as cells commit to myeloid lineages [#1]. In neurons the 1-6-8 isoform is anchored to postsynaptic lipid rafts through N-terminal myristoylation and palmitoylation and binds the regulatory domain of CaMKIIα, establishing a raft-targeted adaptor function [#2]. In leukemia, BAALC functions as an oncogenic scaffold: it binds MEKK1 (MAP3K1) and blocks MKP3/DUSP6-mediated ERK dephosphorylation to sustain ERK activity, while simultaneously sequestering the transcription factor KLF4 in the cytoplasm to block monocytic differentiation, together driving cell-cycle progression and chemoresistance [#9]. It additionally signals through phosphorylation of MK2a (MAPKAPK2), and its loss selectively halts proliferation and induces differentiation of CN/AML blasts without affecting normal HSPCs [#11], and it interacts with the actin-binding protein DBN1 to promote stromal adhesion and microenvironment-mediated chemoresistance [#10]. Functionally, BAALC promotes leukemia cell survival and proliferation, as knockdown reduces growth and increases apoptosis [#6]. Its transcription is activated by a RUNX1-binding promoter SNP and by an SP1/NF-κB complex, and is shaped by histone modifications consistent with a paused promoter state [#7, #8, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing the basic cell biology of BAALC as a cytoplasmic protein with multiple isoforms was the first step toward assigning any function.\",\n      \"evidence\": \"Subcellular localization and genomic/splice-variant analysis in vitro\",\n      \"pmids\": [\"11707601\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Localization inferred in vitro with no functional validation\", \"Roles of individual isoforms undefined\", \"No binding partners identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defining where BAALC is normally expressed linked it to progenitor identity, framing why its dysregulation matters in leukemia.\",\n      \"evidence\": \"FACS sorting of bone marrow subpopulations with RT-PCR plus cytokine-driven differentiation assays\",\n      \"pmids\": [\"14585369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Expression pattern does not establish a causal function\", \"Mechanism of downregulation upon differentiation unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying lipid-raft targeting via lipidation and a direct CaMKIIα interaction revealed BAALC as a membrane-anchored adaptor in neurons.\",\n      \"evidence\": \"Co-IP/pull-down, raft fractionation, and mutagenesis of myristoylation/palmitoylation sites in rat brain\",\n      \"pmids\": [\"15659234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of CaMKIIα binding for synapse physiology not resolved\", \"Whether raft targeting applies to hematopoietic isoforms unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Loss-of-function established BAALC as functionally required for leukemia cell survival rather than merely a marker.\",\n      \"evidence\": \"shRNA knockdown in KG1a AML cells with proliferation and apoptosis readouts\",\n      \"pmids\": [\"22549446\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single cell line\", \"Molecular mechanism downstream of BAALC not addressed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Discovery of a RUNX1-binding promoter SNP explained allele-specific transcriptional control of BAALC and connected it to a master hematopoietic regulator.\",\n      \"evidence\": \"Luciferase reporter and EMSA validated across two AML patient cohorts\",\n      \"pmids\": [\"22493267\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address post-transcriptional or epigenetic layers of regulation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapping the SP1/NF-κB and RUNX1 inputs and the embedded miR-3151 clarified the shared and separable transcriptional control of the BAALC locus.\",\n      \"evidence\": \"Reporter assays, TF-binding studies, and miRNA gain/loss in cell lines and a mouse leukemogenesis model\",\n      \"pmids\": [\"24736457\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of each TF in vivo unclear\", \"Functional separation of miR-3151 vs BAALC effects incomplete\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying the MEKK1 and KLF4 interactions provided the first molecular mechanism by which BAALC sustains ERK signaling and blocks differentiation.\",\n      \"evidence\": \"Reciprocal Co-IP, nuclear/cytoplasmic fractionation, ERK activity assays, and MEK inhibition in vitro and in vivo\",\n      \"pmids\": [\"26050649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of MEKK1 and KLF4 binding not defined\", \"How one scaffold coordinates both interactions unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"NMR backbone assignment provided the first structural foothold for an otherwise poorly characterized protein and showed isoforms share a similar backbone.\",\n      \"evidence\": \"Solution NMR backbone assignment of the 180-residue hematopoietic isoform 1\",\n      \"pmids\": [\"32240523\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No folded domain or interaction interface determined\", \"Functional mapping of structure to partner binding absent\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CRISPR deletion and phosphoproteomics pinpointed MK2a as a BAALC effector and demonstrated a leukemia-selective therapeutic vulnerability.\",\n      \"evidence\": \"CRISPR-Cas9 KO in iPSC-derived CN/AML HSPCs, phosphoproteomics, and CMPD1 inhibition in primary blasts\",\n      \"pmids\": [\"33894142\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link between BAALC and MK2a phosphorylation not shown\", \"Relationship to the ERK/MEKK1 axis not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying the DBN1 interaction connected BAALC to actin-dependent stromal adhesion and microenvironmental chemoresistance.\",\n      \"evidence\": \"Mass spectrometry interaction mapping with DBN1 knockdown adhesion and cytarabine sensitivity assays\",\n      \"pmids\": [\"33453340\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interaction not confirmed by reciprocal Co-IP\", \"Direct vs indirect binding unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Reciprocal gain/loss-of-function in breast cancer cells extended BAALC's pro-tumorigenic scaffold role beyond hematopoiesis via FAK/MMP-9 signaling.\",\n      \"evidence\": \"Overexpression and siRNA knockdown in breast cancer lines with FAK inhibitor and gelatin zymography\",\n      \"pmids\": [\"33968759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BAALC binds FAK directly not established\", \"Generalizability across solid tumors unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single small lipidated scaffold coordinates its distinct partner interactions (MEKK1, KLF4, DBN1, CaMKIIα) and links to MK2a phosphorylation at the structural and biochemical level remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of any BAALC-partner complex\", \"Direct enzymatic versus purely scaffolding role undefined\", \"Mechanism integrating ERK, MK2a, and adhesion pathways unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2, 9, 10]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 3, 9]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"MAP3K1\", \"KLF4\", \"DBN1\", \"CAMK2A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}